Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Mesoblast ( (MESO) ) is now available.
On November 25, 2025, Mesoblast Limited announced at its Annual General Meeting that it has achieved FDA approval for Ryoncil®, a mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. This approval marks a significant milestone for Mesoblast, transitioning the company from development to commercialization with strong sales and reimbursement coverage. The success of Ryoncil® validates Mesoblast’s scientific platform and commercialization strategy, and the company is now expanding its use to additional indications and preparing for further FDA approvals for other products in its pipeline.
The most recent analyst rating on (MESO) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score is driven by financial challenges and bearish technical indicators. Despite strong revenue growth and positive earnings call highlights, the company’s profitability issues and negative valuation metrics weigh heavily on the score. The potential for future growth, as indicated in the earnings call, provides some optimism.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast is a leading company in the development of allogeneic cellular medicines aimed at treating severe and life-threatening inflammatory conditions. The company’s proprietary mesenchymal lineage cell therapy technology platform focuses on responding to severe inflammation by releasing anti-inflammatory factors, significantly reducing the damaging inflammatory process. Mesoblast has a strong global intellectual property portfolio and is listed on the Australian Securities Exchange and Nasdaq.
Average Trading Volume: 240,229
Technical Sentiment Signal: Buy
Current Market Cap: $1.93B
For detailed information about MESO stock, go to TipRanks’ Stock Analysis page.